CoChat

Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Background Mucopolysaccharidosis type IIIB syndrome (also known as Sanfilippo type B syndrome) is a lysosomal storage disease resulting in progressive deterioration of cognitive acquisition after age 2-4 years. No treatment is available for the neurological manifestations of the disease. We sought to assess the safety and efficacy of a novel intracerebral gene therapy.Methods Local regulatory authorities in France allowed inclusion of up to four children in this phase 1/2 study. Treatment was 16 intraparenchymal deposits (four in the cerebellum) of a recombinant adenoassociated viral vector serotype 2/5 (rAAV2/5) encoding human α-N-acetylglucosaminidase (NAGLU) plus immunosuppressive therapy. We assessed tolerance, neurocognitive progression, brain growth, NAGLU enzymatic activity in CSF, and specific anti-NAGLU immune response for 30 months after surgery. This trial is registered with EudraCT, number 2012-000856-33, and the International Standard Clinical Trial Registry, number ISRCTN19853672.Findings Of seven eligible children, the four youngest, from France (n=2), Italy (n=1), and Greece (n=1), aged 20, 26, 30, and 53 months, were included between February, 2012, and February, 2014. 125 adverse events were recorded, of which 117 were treatment emergent and included six classified as severe, but no suspected unexpected serious adverse drug reactions were seen. Vector genomes were detected in blood for 2 days after surgery. Compared with the natural history of mucopolysaccharidosis type III syndromes, neurocognitive progression was improved in all patients, with the youngest patient having function close to that in healthy children. Decrease in developmental quotient was -11·0 points in patient one, -23·0 in patient two, -29·0 in patient three, and -17·0 in patient four, compared with -37·7 in the natural history of the disease. NAGLU activity was detected in lumbar CSF and was 15-20% of that in unaffected children. Circulating T lymphocytes that proliferated and produced tumour necrosis factor α upon ex-vivo exposure to NAGLU antigens were detectable at 1-12 months and 3-12 months, respectively, but not at 30 months in three of four patients.Interpretation Intracerebral rAVV2/5 was well tolerated and induced sustained enzyme production in the brain. The initial specific anti-NAGLU immune response that later subsided suggested acquired immunological tolerance. The best results being obtained in the youngest patient implies a potential window of opportunity. Longer follow-up is needed to further assess safety outcomes and persistence of improved cognitive development.Funding Association Française Contre les Myopathies, Vaincre les Maladies Lysosomales, Institut Pasteur, and UniQure.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(17)30169-2

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 226

Metadata

Authors
Tardieu, M., Zérah, M., Gougeon, M.-L., Ausseil, J., de Bournonville, S., Husson, B., Zafeiriou, D., Parenti, G., Bourget, P., Poirier, B., Furlan, V., Artaud, C., Baugnon, T., Roujeau, T., Crystal, R. G., Meyer, C., Deiva, K., & Heard, J.-M.
Affiliations
  • Université Paris-Sud (FR)
  • Hôpital Necker-Enfants Malades (FR)
  • Institut Pasteur (FR)
  • Aristotle University of Thessaloniki (GR)
  • Telethon Institute Of Genetics And Medicine (IT)
  • Centre Hospitalier Universitaire de Montpellier (FR)
  • Weill Cornell Medicine (US)
  • UniQure (Netherlands) (NL)
  • Inserm (FR)
Corresponding author
Tardieu, Marc
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2017-09
Volume
16
Issue
9
Pages
712-720
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2736152032
Cited by
214
References
31
Citations by year
2026: 7 · 2025: 10 · 2024: 36 · 2023: 21 · 2022: 28 · 2021: 34 · 2020: 33 · 2019: 15 · 2018: 21 · 2017: 8
FWCI
15.57
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
Keywords
mucopolysaccharidosis type IIIB, Sanfilippo syndrome, recombinant adeno-associated virus vectors, AAV2/5, NAGLU, alpha-N-acetylglucosaminidase, lysosomal storage disease, immunosuppressive therapy
MeSH terms
Acetylglucosaminidase, Dependovirus, Brain, Child, Preschool, Genetic Vectors, Humans, Immunosuppressive Agents, Infant, Mucopolysaccharidosis III, Syndrome, Genetic Therapy, Outcome Assessment, Health Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. https://app.cochat.ai/papers/10.1016/s1474-4422(17)30169-2
The paper
Tardieu, M., Zérah, M., Gougeon, M.-L., Ausseil, J., de Bournonville, S., Husson, B., Zafeiriou, D., Parenti, G., Bourget, P., Poirier, B., Furlan, V., Artaud, C., Baugnon, T., Roujeau, T., Crystal, R. G., Meyer, C., Deiva, K., & Heard, J.-M. (2017). Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(17)30169-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.